Download PDF
neuroreha 2010; 2(3): 126-132
DOI: 10.1055/s-0030-1265124
Schwerpunkt Tonuserhöhung: Aus der Praxis
© Georg Thieme Verlag KG Stuttgart · New York

Therapeutische Maßnahmen zur Tonusreduktion

Michael Jöbges
Further Information

Publication History

Publication Date:
06 September 2010 (online)

    Permissions and Reprints

Zusammenfassung

Die spastische Erhöhung des Muskeltonus im Rahmen eines Upper-Motor-Neuron-Syndroms ist nicht statisch, es handelt sich um einen dynamischen Prozess. Eine erfolgreiche Behandlung ist selten durch eine singuläre Therapiemaßnahme zu erreichen. Vielmehr ist die Kombination von physio- und ergotherapeutischen Therapien, einer Hilfsmittelversorgung, oraler Medikation bzw. fokalen Techniken und der Anleitung zum Selbstmanagement in der Behandlung sinnvoll.

Literatur

  • 01 Ada L , O’Dwyer N , O’Neill E . Relation between spasticity, weakness and contracture of the elbow flexors and upper limb activity after stroke: an observational study.  Disabil Rehabil. 2006;  28 891-897
    Google Scholar
  • 02 Barnes M P. Local treatment of spasticity.  Bailliere‘s Clin Neurol. 1993;  2 5-71
    Google Scholar
  • 03 Bell K R, Lehmann J F. Effect of cooling on H- and T-reflexes in normal subjects.  Arch Phys Med Rehabil. 1987;  68 490-493
    Google Scholar
  • 04 Blasi J , Chapmann E , Link E  et al.. Botulinum neurotoxin A selectively cleaves the synapse protein SNAP-25.  Nature. 1993;  365 160-163
    Google Scholar
  • 05 Bohannon R , Larkin P . Passive ankle dorsiflexion increases in patients after a regimen of tilt table-wedge board standing.  Phys Ther. 1985;  65 1676-1678
    Google Scholar
  • 06 Boyd R A, Ada L . Physiotherapy management of spasticity. In: Barnes M P, Johnson G R Upper Motor Neuron Syndrome and Spasticity. New Cambridge University Press; Cambridge; 2008: 79-98
    Google Scholar
  • 07 Bruton A . Muscle plasticity: response to training and de-training.  Physiotherapy. 2002;  88 398-408
    Google Scholar
  • 08 Burridge J H, Taylor P N, Hagan S A et al.. The effects of common peroneal stimulation on the effort and speed of walking: a randomized controlled trial with chronic hemiplegic patients.  Clin Rehabil. 1997;  11 201-210
    Google Scholar
  • 09 Bütefisch  C , Hummelsheim H , Denzler P  et al.. Repetitive training of isolated movements improves the outcome of motor rehabilitation of the centrally paretic hand.  J Neurol Sci. 1995;  130 59-68
    Google Scholar
  • 10 Coward D M. Tizanidine: Neuropharmacology and mechanisms of action.  Neurology. 1994;  44 6-11
    Google Scholar
  • 11 Duncan G W, Shahani B T, Young R R. An evaluation of baclofen treatment for certain symptoms in patients with spinal cord lesions: a double blind cross over study.  Neurology. 1976;  26 441-446
    Google Scholar
  • 12 Eng J , Levins S , Towson A  et al.. Use of prolonged standing for individuals with spinal cord injuries.  Phys Ther. 2001;  81 1392-1399
    Google Scholar
  • 13 Fujiwar T , Kasashima Y , Honaga K  et al.. Motor improvement and corticospinal modulation induced by hybrid assistive neuromuscular dynamic stimulation (HANDS) therapy in patients with chronic stroke.  Neurorehab Neural Repair. 2009;  23 125-132
    Google Scholar
  • 14 Hattab J R. Review of European clinical trial with baclofen. In: Feldman R G, Young R R, Koella W P, Eds Spasticity: Disordered Motor Control. Year Book Medical Publishers; Chicago; 1980: 71-85
    Google Scholar
  • 15 Hedenberg L . Functional improvement of spastic hemiplegic arm after coolin.  Scand J Rehabil Med. 1970;  2 154-158
    Google Scholar
  • 16 Henry J L. Pharmacological studies on baclofen in the spinal cord of the rat. In: Feldman R G, Young R R, Koella W P, Eds Spasticity: Disordered Motor Control. Year Book Medical Publishers; Chicago; 1980: 437-452
    Google Scholar
  • 17 Hesse S , Konrad M , Uhlenbrock D . Treadmill walking with partial body weight support versus floor walking in hemiparetic subjects.  Arch Phys Med Rehabil. 1999;  80 421-427
    CrossrefGoogle Scholar
  • 18 Kunze Klaus . Untersuchung und Diagnose. In: Kunze K  Praxis der Neurologie. 2. Auflage Thieme; Stuttgart; 1999: 2-62
    Google Scholar
  • 19 Kocsis S , Farkas S , Fodor L  et al.. Tolperisone-type drugs inhibit spinal reflexes via blockade of voltage gated sodium and calcium channels.  J Pharmacol Exp Ther. 2005;  315 1237-1246
    CrossrefGoogle Scholar
  • 20 Lai J M, Francisco  G E, Willis F B. Dynamic splinting after treatment with botulinum toxin type-a: a randomized controlled pilot study.  Adv Ther. 2009;  26 241-248
    CrossrefGoogle Scholar
  • 21 Laitinen L V, Nilsson S , Fugl-Meyer A R. Selective posterior rhizotomy for treatment of spasticity.  J Neurosurg. 1983;  58 895-899
    CrossrefGoogle Scholar
  • 22 Lange O , Bigalke H , Dengler R  et al.. Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing?.  Clin Neuropharmacol. 2009;  32 213-218
    CrossrefGoogle Scholar
  • 23 Lockley L J, Buchanan K . Physical management of spasticity. In: Stevenson V L, Jarrett L ,   , et al., (Hrsg.) Spasticity management. Taylor & Francis; Boca Raton; 2006: 37-58
    Google Scholar
  • 24 Mehrholz J , Wagner K , Meißner D  et al.. Reliability of the modified Tardieu scale and the modified Ashworth scale in adult patients with severe brain injury: a comparison study.  Clin Rehabil. 2005;  19 751-759
    CrossrefPubMedGoogle Scholar
  • 25 Mortenson P A, Eng J J. The use of casts in the management of joint mobility and hypertonia following brain injury in adults: a systematic review.  Phys Ther. 2003;  83 648-658
    Google Scholar
  • 26 Mueller M E, Gruenthal M , Olson W L et al.. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis.  Arch Phys Med Rehabil. 1997;  78 521-524
    CrossrefGoogle Scholar
  • 27 Ochs G , Struppler A , Meyerson B A et al.. Intrathecal baclofen for long-term treatment of spasticity: a multi-centre study.  J Neurol Neurosurg Psychiatry. 1989;  52 933-939
    CrossrefGoogle Scholar
  • 28 O‘Dwyer N J, Ada L , Neilson  P D. Spasticity and muscle contracture following stroke.  DGN Leitlinie 2008 Therapie des spastischen Syndroms Brain. 1996;  119 1737-1749
    CrossrefGoogle Scholar
  • 29 Pinder R M, Brodgen R N, Speight T M et al.. Dantrolene sodium: a review of its pharmacological properties and therapeutic efficacy in spasticity.  Drugs. 1977;  13 3-23
    CrossrefGoogle Scholar
  • 30 Price R , Lehmann J F. Influence of muscle cooling on the viscoelastic response of the human ankle to sinusoidal displacements.  Arch Phys Med Rehabil. 1990;  71 745-748
    PubMedGoogle Scholar
  • 31 Price G , Wilkin G P, Turnbull M J et al.. Are baclofen sensitive GABA-B receptors present on primary afferent terminals of the spinal cord?.  Nature. 1984;  307 71-73
    CrossrefGoogle Scholar
  • 32 Putty T K, Shapiro S A. Efficacy of dorsal longitudinal myelotomy in treating spinal spasticity: a review of 20 cases.  J Neurosurg. 1991;  75 397-401
    CrossrefGoogle Scholar
  • 33 Roussan M , Terrence C , Fromm G . Baclofen versus diazepam for the treatment of spasticity and long term follow-up of baclofen-therapy.  Pharmacotherapeutica. 1987;  4 278-284
    Google Scholar
  • 34 Schantz E J, Johnson E A. Botulinum toxin: the story of the development for the treatment of human disease.  Perspect Biol Med. 1997;  40 317-327
    Google Scholar
  • 35 Schmit B D, Dewald J P, Rymer W Z. Stretch reflex adaptation in elbow flexors during repeated passive movements in unilateral brain-injured patients.  Ach Phys Med Rehabil. 2000;  81 269-278
    Google Scholar
  • 36 Simpson D M, Alexander D N, O’Brian C F et al.. Botulinum toxin type a in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial.  Neurology. 1996;  46 1306-1310
    CrossrefGoogle Scholar
  • 37 Stamenova P , Koytchev R , Kuhn K  et al.. A randomized double-blind, placebo-controlled study of the efficacy and safety of tolperisone in spasticity following cerebral stroke.  Eur J Neurol. 2005;  12 453-461
    CrossrefGoogle Scholar
  • 38 Stien R , Nordal H J, Oftedal S I et al.. The treatment of spasticity in multiple sclerosis: a double-blind clinical trial of a new anti-spastic drug tizanidine compared with baclofen.  Act Neurol Scand. 1987;  75 190-194
    Google Scholar
  • 39 Teixeira-Salmela L F, Olney S J, Nadeau S  et al.. Muscle strengthening and physical conditioning to reduce impairment and disability in chronic stroke survivors.  Arch Phys Med Rehabil. 1999;  80 1211-1218
    CrossrefGoogle Scholar
  • 40 Ward A , Chaqffmann H O, Sorkin E M et al.. Dantrolene: a review of its pharmacokinetic properties and therapeutic use in malignant hyperthermia, the malignant neuroleptic syndrome and an update of its use in muscle spasticity.  Drugs. 1986;  32 130-186
    CrossrefPubMedGoogle Scholar
  • 41 Winchester P , Montgomery J , Bowman B  et al.. Effects of feedback stimulation training and cyclicalo electrical stimulation on knee extension in hemiparetic patients.  Phys Ther. 1983;  63 1096-1103
    Google Scholar
  • 42 Woldag H , Hummelsheim H  . Is the reduction of spasticity by botulinum toxin a beneficial for the recovery of motor function of arm and hand in stroke patients?.  Eur Neurol. 2003;  50 165-171
    CrossrefGoogle Scholar
  • 43 Zander C L, Healy N L. Elbow flexion contractures treated with serial casts and conservative therapy.  J Hand Surg Am. 1992;  17 694-697
    CrossrefGoogle Scholar

Dr. med. Michael Jöbges

Brandenburg Klinik

Brandenburgallee 1

16321 Bernau bei Berlin

Phone: 033397/34001

Fax: 033397/34044

Email: joebges@brandenburgklinik.de

      >